Cendakimab successful in EoE across IL-13 variants

Cendakimab is a safe and efficacious therapy for patients with eosinophilic oesophagitis (EoE), irrespective of IL-13 variations, according to data from a phase 3 study.

IL-13 is a cytokine that is relevant for the pathogenesis of EoE. Cendakimab is a recombinant humanised anti-IL-13 monoclonal antibody, blocking interaction with both of its receptors. “Since certain IL-13 variants have enhanced biological activities, our study assessed the effect of IL-13 variants on the efficacy and safety of cendakimab,” said Dr Jie Li (Bristol Myers Squibb, NJ, USA) [1]. The presented phase 3 trial (NCT04753697) included 427 patients with EoE. Participants were randomised to cendakimab, 360 mg weekly, subcutaneously administered, or to placebo. The investigators genotyped IL-13 single-nucleotide polymorphisms (SNPs) and looked at associations between IL-13 SNP genotype and the clinical efficacy and safety of cendakimab. The co-primary endpoints were the mean change from baseline in dysphagia days and a histologic response of eosinophils ≤6 per high-power field.

At 24 weeks of follow-up, there was no influence of SNP genotype on the efficacy of cendakimab in the treated arm. Also, no SNP genotypes were associated with an increased risk for respiratory infection.

“IL-13 SNP genotypes did not significantly impact the efficacy or safety–from the respiratory infection standpoint–of cendakimab, suggesting that cendakimab is efficacious and safe in patients with EoE, regardless of target variations,” concluded Dr Li.

1. Li J, et al. Cendakimab is an effective and safe treatment for patients with eosinophilic esophagitis regardless of interleukin 13 variations: results from a phase 3 trial. Abstract Mo1352, Digestive Disease Week 2025, 3–6 May 2025, San Diego, USA.

Copyright ©2025 Medicom Medical Publishers



Posted on 21 May 202521 May 2025